Plasma follistatin is elevated in patients with type 2 diabetes: relationship to hyperglycemia, hyperinsulinemia, and systemic low‐grade inflammation

• DOI: 10.1002/dmrr.2415
• Publication Date: 2013-04-06T12:08:39Z
• Authors: J. Hansen; A. Rinnov; R. Krogh‐Madsen; C. P. Fischer; A. S. Andreasen; R. M. G. Berg; K. Møller; B. K. Pedersen; P. Plomgaard
• Keywords: Follistatin; Hyperinsulinemia

Abstract Background Plasma follistatin is elevated in patients with low‐grade inflammation and insulin resistance as observed polycystic ovary syndrome. In the present study, we evaluated plasma type 2 diabetes characterised by assessed acute effects of hyperglycemia, hyperinsulinemia LPS on follistatin. Methods Baseline inflammatory biomarkers were measured a cross‐sectional study that involved 95 103 matched controls. To determine effect hyperglycemia follistatin, hyperglycemic hyperinsulinemic‐euglycemic clamps performed five healthy males. Furthermore, 15 22 controls challenged low‐dose to Results Patients have higher HOMA2‐IR values mean [95% CI] 1.64 [1.40–1.93] versus 0.86 [0.75–0.99], p < 0.001 markers compared 1564 [1456–1680] 1328 [1225–1440] ng/L, = 0.003 correlates fasting glucose levels ( r 0.44, 0.0001), h 0.48, HbA 1c 0.41, triacylglycerol 0.28, 0.008) total cholesterol 0.33, 0.004) but not No correlation exists between either groups. Neither nor increase Conclusions moderately diabetes. Our findings suggest this likely caused or systemic inflammation. Copyright © 2013 John Wiley & Sons, Ltd.